In this clinical session, experts will provide a thorough exploration of the ever-evolving landscape in managing the intricate interplay among cardiovascular (CV) health, kidney function, and metabolic factors. Coined as Cardiovascular-Kidney-Metabolic (CKM) Syndrome, this phenomenon has emerged as a pivotal nexus where obesity, diabetes, chronic kidney disease (CKD), and CV issues intersect. A significant development in the field is the updated 2023 Clinical Practice Guideline for the Evaluation and Management of CKD by KDIGO, building upon the foundation laid in 2012. The session will not only examine these forthcoming renal guidelines but will also dissect the unique challenges faced by individuals with established CV disease and concurrent metabolic risk factors or CKD. This exploration will shed light on nuanced management considerations, emphasizing the importance of staying abreast of the latest developments. Despite the wealth of existing literature supporting current scientific understanding and approaches to the prevention and management of CKM syndrome, critical knowledge gaps persist. This presentation will confront key limitations in the available data that underpins clinical care for CKM syndrome. Topics to be addressed include early-life prevention, effective screening for risk factors, interdisciplinary care models, optimal strategies for lifestyle modification and weight loss, as well as targeting emerging cardioprotective and kidney-protective therapies. Furthermore, the session will delve into the challenges of managing patients with both cardiovascular disease and chronic kidney disease, providing valuable insights into the impact of systematically assessing and addressing social determinants of health.

Faculty

Moderator: Lavinia Salama, Pharm.D., BCACP, BC-ADM, CDE   View Biography